Denali therapeutics announces completion of enrollment for regimen g evaluating eif2b agonist dnl343 in the phase 2/3 healey als platform trial

South san francisco, calif., may 01, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the sean m. healey & amg center in collaboration with the northeast als consortium (neals) completed enrollment for regimen g of the phase 2/3 healey als platform trial , which evaluates denali's eif2b agonist dnl343.
DNLI Ratings Summary
DNLI Quant Ranking